Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Thursday 16 July 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Market Access

judgement concept with gavel by pills

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Digital

Konovo webinar wrap up cover image

Sponsored

Delivering smarter, faster insights for better health outcom...

In a recent webinar, Konovo experts addressed some of the critical topics impacting today’s healthcare market research.

Digital

cybersecurity concept of lock on hardware

Stolen patient data is now a structured commodity

When it comes to cybersecurity, healthcare data security should concern every provider and pharmaceutical organisation: medical records do not expire.

Sales & Marketing

pharmaphorum podcast Episode 268 - Andrea Carta Mantiglia, BonelliErede

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, discusses M&A in Europe.

Oncology

ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad

ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad

In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto

R&D

parental permission, child assent, and consent in clinical trials

Parental permission, child assent, and adolescent autonomy i...

As a vulnerable population, children in general must rely on their parents or guardians to provide informed consent for them to participate in research.

R&D

This week in clinical trials

This week in clinical trials: 20th to 24th May

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.

Market Access

cell and gene therapies

Collaboration is key to tackling geographical boundaries in ...

Unlike most biopharmaceuticals, it is often a struggle to manufacture cell and gene therapies (CGTs) in disparate geographies.

Load more results

Sales & Marketing

Sales & Marketing

pharmaphorum podcast Episode 268 - Andrea Carta Mantiglia, BonelliErede

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, discusses M&A in Europe.

Sales & Marketing

12 Questions with Kevin Asher, Acumetis

Sponsored

12 Questions with Kevin Asher

Kevin Asher leads Acumetis's Medical Practice, bringing 15+ years in Medical Affairs to teams across the industry.

Digital

Digital

Konovo webinar wrap up cover image

Sponsored

Delivering smarter, faster insights for better health outcom...

In a recent webinar, Konovo experts addressed some of the critical topics impacting today’s healthcare market research.

Digital

cybersecurity concept of lock on hardware

Stolen patient data is now a structured commodity

When it comes to cybersecurity, healthcare data security should concern every provider and pharmaceutical organisation: medical records do not expire.

Market Access

Market Access

judgement concept with gavel by pills

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Market Access

Board meeting, blurred colour image

Changing Faces: Boards of Directors and Advisory Boards, May...

The latest Board moves reflect a focus on experience in commercialisation, corporate governance, and therapeutic development.

Editor's Picks

Vertex buys Crinetics for $10bn in endocrinology drive

UK first in Europe to clear Boehringer's IPF drug Jascayd

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Island Pharma drug cleared for Bundibugyo Ebola use

NICE backs NHS use of non-invasive endometriosis tests

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

lung cancer

EGFR-mutant lung cancer: Cracking the drug resistance code

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.

Oncology

ASCO 2026: All about DNA damage response, with Luke Piggot

ASCO 2026: All about DNA damage response, with Luke Piggot

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Oncology

Oncology liquid biopsies

Are liquid biopsies finally finding their place in cancer ca...

Patients

Patients

Patients at the table in discussions

Moving from patient centricity to patient partnership

The desire for patients to be active partners in research challenges how organisations approach patient engagement.

Patients

An elderly man receives at-home care

End-of-life choice means little without end-of-life support

A strong end-of-life care system does not wait until the final days to step in.

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

R&D

R&D

Gothenburg skyline at sunset

Go north: Life sciences excellence shines bright in Sweden

Gothenburg is Sweden's fastest-growing and second largest city region and one of Europe's leading innovation regions.

R&D

pharmaphorum podcast Episode 267, Haseeb Ahmad - Purespring Therapeutics

Purespring on nephrology & gene therapy in kidney disease

Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.

R&D

Elderly lady smiling with gentle sunlight behind her

Sponsored

What European Commission marketing authorisation of a teripa...

Biosimilars can help support broader patient access while contributing to the long-term sustainability of healthcare systems.

Editor's Picks

Vertex buys Crinetics for $10bn in endocrinology drive

UK first in Europe to clear Boehringer's IPF drug Jascayd

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Island Pharma drug cleared for Bundibugyo Ebola use

NICE backs NHS use of non-invasive endometriosis tests

News

MSD gets first FDA okay for oral PCSK9 cholesterol drug

MSD gets first FDA okay for oral PCSK9 cholesterol drug

MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval for LDL cholesterol-lowering in the US.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company